Yanzhi Hsu

Title: Yanzhi Hsu: Innovator in Antibody Therapy for Hepatocellular Carcinoma

Introduction

Yanzhi Hsu is a prominent inventor based in Basking Ridge, NJ (US). He has made significant contributions to the field of medical research, particularly in the development of therapies for cancer treatment. His innovative work focuses on antibody therapies that target specific receptors involved in cancer progression.

Latest Patents

Yanzhi Hsu holds a patent for an "Anti-VEGFR2 antibody therapy for hepatocellular carcinoma." This invention provides a human antibody that binds to the human vascular endothelial growth factor receptor 2, specifically ramucirumab. The therapy is designed for the treatment of hepatocellular carcinoma (HCC) in patients with alpha-fetoprotein (AFP) levels of 1.5×ULN (Upper Limit of Normal) or greater. Additionally, it serves as a predictive method for treating HCC in these patients.

Career Highlights

Hsu's career is marked by his dedication to advancing cancer treatment through innovative therapies. He has been instrumental in developing targeted therapies that improve patient outcomes. His work has garnered attention in the medical community, highlighting the importance of precision medicine in oncology.

Collaborations

Yanzhi Hsu collaborates with esteemed colleagues, including Paolo B Abada and Shao-Chun Chang. These partnerships enhance the research and development of effective cancer therapies, fostering a collaborative environment that drives innovation.

Conclusion

Yanzhi Hsu's contributions to antibody therapy for hepatocellular carcinoma exemplify the impact of innovative research in medicine. His work not only advances treatment options but also paves the way for future discoveries in cancer therapy.